MINGJIE SUN – Trademark Portfolio

Entity Type: 01

MINGJIE SUN holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 27 (Floor Coverings) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include CICOMAX. The owner is based in LINYI, SHANDONG.

NO.227. HUANGTUNIAN VIL., FRONT OF LUOXI OFFICE

LINYI HIGH-TECH ZONE, LUOZHUANG DIST.

LINYI, SHANDONG 276000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

LANBORO
LANBORO
Pending 2025
CICOMAX
CICOMAX
Registered 2021

Trademark Classifications

MINGJIE SUN's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

27
Floor Coverings (1 filing)

Carpets, rugs, mats and matting, linoleum and other materials for covering floors

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does MINGJIE SUN have?

MINGJIE SUN has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.

What trademark classes does MINGJIE SUN file in?

MINGJIE SUN files trademarks across 2 Nice Classification classes. The most active classes are Class 27 (Floor Coverings), Class 5 (Pharmaceuticals). Class 27 covers carpets, rugs, mats and matting, linoleum and other materials for covering floors.

What are MINGJIE SUN's most well-known trademarks?

MINGJIE SUN's registered trademark portfolio includes well-known marks such as CICOMAX. These are among 1 currently registered trademark in the portfolio.

What is MINGJIE SUN's trademark registration success rate?

MINGJIE SUN has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.